The Remote Assessment of Disease and Relapse – Alzheimer’s Disease (RADAR-AD) consortium evaluated remote measurement technologies (RMTs) for assessing functional status in AD. The consortium engaged with the European Medicines Agency (EMA) to obtain feedback on identification of meaningful functional domains, selection of RMTs and clinical study design to assess the feasibility of using RMTs in AD clinical studies. We summarized the feedback and the lessons learned to guide future projects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375004 | PMC |
| http://dx.doi.org/10.1038/s41746-024-01211-8 | DOI Listing |
Publication Analysis
Top Keywords
remote measurement
8
measurement technologies
8
rmts clinical
8
regulatory considerations
4
considerations developing
4
developing remote
4
technologies alzheimer's
4
alzheimer's disease
4
disease remote
4
remote assessment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!